Randomization and statistical power: paramount in trial reproducibility (even for rare cancers)

Oncologist. 2012;17(9):1129-32. doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.

Authors

Laurence H Baker¹, John J Crowley, Robert G Maki

Affiliation

¹ D.O., Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, Michigan 48106, USA. bakerl@med.umich.edu

Abstract

This article comments on the importance of randomization and statistical power in clinical trials.

Publication types

Comment

MeSH terms

Deoxycytidine / analogs & derivatives*
Deoxycytidine / therapeutic use
Docetaxel
Female
Gemcitabine
Humans
Leiomyosarcoma / drug therapy*
Male
Taxoids / therapeutic use*

Substances

Taxoids
Deoxycytidine
Docetaxel
Gemcitabine